HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Adjusts Price Target To $10
SAB Biotherapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)
Keay Nakae Rates SAB Biotherapeutics as a Buy: Strong Financial Position and Promising Developments in Type 1 Diabetes Treatment
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $1
SAB Biotherapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: SAB Biotherapeutics (SABS), Elevance Health (ELV)
SAB Biotherapeutics' Financial Stability and Potential Growth: A Comprehensive Analysis of Edward White's Buy Rating
Secured Financing and Promising Clinical Developments Bolster Buy Rating for SAB Biotherapeutics
SAB Biotherapeutics Analyst Ratings
SAB Biotherapeutics (SABS) Gets a Buy From Chardan Capital
SAB Biotherapeutics (SABS) Receives a Buy From H.C. Wainwright
SAB Biotherapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $4 Price Target
SAB Biotherapeutics (SABS) Receives a Buy From H.C. Wainwright
H.C. Wainwright Remains a Buy on SAB Biotherapeutics (SABS)
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Geron (GERN)
Chardan Capital Reiterates Buy on SAB Biotherapeutics, Maintains $3 Price Target
SAB Biotherapeutics (SABS) Gets a Buy From Chardan Capital
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $4 Price Target
No Data